Search research articles
Contact Us
Filters
Showing results (11-20 of 114) with videos related to
Page
of 12
Sort By:
Drug Discovery Today
|
May 28, 2025
Insights from the European Medicines Agency on digital health technology derived endpoints
Keerti D Jadoenathmisier, Helga Gardarsdottir, Peter G M Mol, et al.
Clinical Pharmacology and Therapeutics
|
January 6, 2023
Safety-Related Drug Label Changes Following Large Post-Marketing Cardiometabolic Trials: A Review of European Public Assessment Reports
Viktoriia Starokozhko, Fatima Tarrahi, Patrick J W S Vrijlandt, et al.
Diabetes, Obesity & Metabolism
|
October 9, 2018
Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations
Peter G M Mol, Aliza Thompson, Hiddo J L Heerspink, et al.
Drug Safety
|
September 2, 2011
Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the international society of pharmacovigilance (ISoP), 2010
Priya Bahri, Peter G M Mol, Hélène Théophile, et al.
Clinical Pharmacology and Therapeutics
|
October 18, 2022
Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making
Elisabeth Bakker, Kelly Plueschke, Carla J Jonker, et al.
Drug Safety
|
September 15, 2022
Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands
Esther de Vries, Elisabeth Bakker, Taco B M Monster, et al.
Clinical Pharmacology and Therapeutics
|
April 29, 2024
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report
Anna M G Pasmooij, Peter G M Mol, Jacob Cornelis Bot, et al.
Eclinicalmedicine
|
November 12, 2019
Smart Medication Adherence Monitoring in Clinical Drug Trials: A Prerequisite for Personalised Medicine?
Tanja R Zijp, Peter G M Mol, Daan J Touw, et al.
Tropical Medicine & International Health : TM & IH
|
February 6, 2013
Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009
Veronika J Wirtz, Peter G M Mol, Jonneke Verdijk, et al.
British Journal of Clinical Pharmacology
|
July 19, 2019
Future of the drug label: Perspectives from a multistakeholder dialogue
Christine C Gispen-de Wied, Just Weemers, Wouter Boon, et al.
Page
of 12
Search research articles
Search
Showing results (11-20 of 114) with videos related to
Sort By:
Page
of 12
Drug Discovery Today
|
May 28, 2025
Insights from the European Medicines Agency on digital health technology derived endpoints
Keerti D Jadoenathmisier, Helga Gardarsdottir, Peter G M Mol, et al.
Clinical Pharmacology and Therapeutics
|
January 6, 2023
Safety-Related Drug Label Changes Following Large Post-Marketing Cardiometabolic Trials: A Review of European Public Assessment Reports
Viktoriia Starokozhko, Fatima Tarrahi, Patrick J W S Vrijlandt, et al.
Diabetes, Obesity & Metabolism
|
October 9, 2018
Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations
Peter G M Mol, Aliza Thompson, Hiddo J L Heerspink, et al.
Drug Safety
|
September 2, 2011
Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the international society of pharmacovigilance (ISoP), 2010
Priya Bahri, Peter G M Mol, Hélène Théophile, et al.
Clinical Pharmacology and Therapeutics
|
October 18, 2022
Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making
Elisabeth Bakker, Kelly Plueschke, Carla J Jonker, et al.
Drug Safety
|
September 15, 2022
Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands
Esther de Vries, Elisabeth Bakker, Taco B M Monster, et al.
Clinical Pharmacology and Therapeutics
|
April 29, 2024
The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report
Anna M G Pasmooij, Peter G M Mol, Jacob Cornelis Bot, et al.
Eclinicalmedicine
|
November 12, 2019
Smart Medication Adherence Monitoring in Clinical Drug Trials: A Prerequisite for Personalised Medicine?
Tanja R Zijp, Peter G M Mol, Daan J Touw, et al.
Tropical Medicine & International Health : TM & IH
|
February 6, 2013
Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009
Veronika J Wirtz, Peter G M Mol, Jonneke Verdijk, et al.
British Journal of Clinical Pharmacology
|
July 19, 2019
Future of the drug label: Perspectives from a multistakeholder dialogue
Christine C Gispen-de Wied, Just Weemers, Wouter Boon, et al.
Page
of 12